BCL2 and lung adenocarcinoma: OPA1 participates in resistance against the tyrosine kinase inhibitor gefitinib in lung adenocarcinoma [35], the Bcl-2 antagonist Venetoclax in acute myeloid leukemias [36], and in the development of residual disease following standard-of-care treatment for TNBC [18].